81. Amyotrophic Lateral Sclerosis (ALS) - Medical Dictionary Definitions Of Popular MedicineNet Home MedTerms medical dictionary AZ List amyotrophic lateral sclerosis (ALS). Advanced Search. amyotrophic lateral sclerosis (ALS) Index. http://www.medterms.com/script/main/art.asp?articlekey=2231

82. ALS (amyotrophic Lateral Sclerosis) - Medical Dictionary Definitions Of Popular MedicineNet Home MedTerms medical dictionary AZ List ALS (amyotrophic lateral sclerosis). Advanced Search. ALS (amyotrophic lateral sclerosis) Index. http://www.medterms.com/script/main/art.asp?articlekey=2210

83. CCHS Clinical Digital Library amyotrophic lateral sclerosis Clinical Resources. Chapter 365 amyotrophic lateral sclerosis and Other Motor Neuron Diseases Table of contents http://cchs-dl.slis.ua.edu/clinical/neurology/neuromusculardisorders/als.htm

Clinical Resources by Topic: Neurology Amyotrophic Lateral Sclerosis Clinical Resources Emergency Geriatrics Pathology Genetics ... Miscellaneous Resources See also: Neurological Clinical Procedure Resources General Neurology Clinical Resources Amyotrophic Lateral Sclerosis Patient/Family Resources Harrison's Principles of Internal Medicine 15th Ed.-2001: Table of contents Health Sciences Library subscription INFO Chapter 365: Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases Table of contents Amyotrophic Lateral Sclerosis: Access document Treatment: Access document Goetz: Textbook of Clinical Neurology 2nd Ed.-2003 (MD Consult): Table of contents Health Sciences Library subscription INFO Chapter 15 - Strength and Reflexes: Access document History and Definitions: Access document Clinical History: Access document Anatomy of Strength and Reflexes: Access document Examination of Strength and Reflexes: Access document Evaluation Guidelines: Access document Clinical Syndromes: Access document General Management Goals: Access document Reviews and Selected Updates: Access document References: Access document Chapter 36 - Degenerative Motor, Sensory, and Autonomic Disorders:

84. Riluzole For Amyotrophic Lateral Sclerosis (ALS)/motor Neuron Disease (MND) (Coc All rights reserved. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) (Cochrane Review). Miller RG, Mitchell JD, Lyon M and Moore DH. http://www.update-software.com/abstracts/AB001447.htm

From The Cochrane Library, Issue 2, 2004 Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) (Cochrane Review) Miller RG, Mitchell JD, Lyon M and Moore DH ABSTRACT Order full review View and/or submit comments What's new in this issue Search abstracts ... Browse by Review Group A substantive amendment to this systematic review was last made on 20 February 2002. Cochrane reviews are regularly checked and updated if necessary. Background: Riluzole has been approved for treatment of patients with amyotrophic lateral sclerosis in many countries but not all. Questions persist about its clinical utility because of high cost, modest efficacy and concern over adverse effects. Objectives: To examine the efficacy of riluzole in prolonging survival, and in delaying the use of surrogates (tracheostomy and mechanical ventilation) to sustain survival. Search strategy: Search of the Cochrane Neuromuscular Disease Group Register for randomized trials and enquiry from authors of trials, Aventis (manufacturer of riluzole) and other experts in the field. The most recent search was November 2002. Selection criteria: Types of studies: randomized trialsTypes of participants: adults with a diagnosis of amyotrophic lateral sclerosisTypes of interventions: treatment with riluzole or placeboTypes of outcome measures:Primary: pooled hazard ratio of tracheostomy-free survival over all time points with riluzole 100 mg. Secondary: per cent mortality as a function of time with riluzole 100 mg and other doses of riluzole; neurologic function, quality of life, muscle strength and adverse events.

85. Treatment For Spasticity In Amyotrophic Lateral Sclerosis/motor Neuron Disease ( All rights reserved. Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease (Cochrane Review). Ashworth NL, Satkunam LE, Deforge D. http://www.update-software.com/abstracts/AB004156.htm

From The Cochrane Library, Issue 2, 2004 Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease (Cochrane Review) Ashworth NL, Satkunam LE, Deforge D ABSTRACT Order full review View and/or submit comments What's new in this issue Search abstracts ... Browse by Review Group A substantive amendment to this systematic review was last made on 14 November 2003. Cochrane reviews are regularly checked and updated if necessary. Background: Spasticity commonly affects patients with motor neuron disease and it is likely to contribute to worsening muscle dysfunction, increased difficulty with activities of daily living and deteriorating quality of life. Objectives: The objective of this review is to systematically review all types of treatments for spasticity in amyotrophic lateral sclerosis, also known as motor neuron disease. Search strategy: We searched the Cochrane Neuromuscular Disease Group specialised trials register (searched January 2003), MEDLINE (January 1966 to January 2003), EMBASE (January 1980 to January 2003), CINAHL (January 1982 to January 2003), AMED (January 1985 to January 2003) and LILACS (January 1982 to January 2003) for randomized controlled trials. We reviewed the bibliographies of the randomized trials identified, and contacted trial authors and known experts in the field. Selection criteria: We included quasi-randomized or randomized controlled trials of participants with probable or definite amyotrophic lateral sclerosis according to the El Escorial diagnostic criteria (or a revised version) or the Airlie House revision. We would have included trials of physical therapy, modalities, prescription medications, non-prescription medications, chemical neurolysis, surgical interventions, alternative therapies. Our primary outcome measure was reduction in spasticity at three months or greater as measured by Ashworth (or modified Ashworth) spasticity scale. Our secondary outcome measures were: validated measures based on history, physical examination, physiological measures, measures of function, measures of quality of life, serious adverse events, and measures of cost.

86. Amyotrophic Lateral Sclerosis amyotrophic lateral sclerosis ALS. Book, Home Page. http://www.fpnotebook.com/NEU157.htm

Home About Links Index ... Editor's Choice document.write(code); Advertisement Neurology Motor Assorted Pages Amyotrophic Lateral Sclerosis Cataplexy Cervical Dystonia Guillain Barre Syndrome ... Right Hemiplegia Amyotrophic Lateral Sclerosis ALS Book Home Page Cardiovascular Medicine Dentistry Dermatology Emergency Medicine Endocrinology Gastroenterology General Medicine Geriatric Medicine Gynecology Hematology and Oncology HIV Infectious Disease Jokes Laboratory Neonatology Nephrology Neurology Obstetrics Ophthalmology Orthopedics Otolaryngology Pediatrics Pharmacology Prevention Psychiatry Pulmonology Radiology Rheumatology Sports Medicine Surgery Urology Chapter Neurology Index Autonomic Cerebellum Chorea Cranial Nerve Cognitive CSF Cardiovascular Medicine Demyelinating Dermatology Disability Examination Ophthalmology Geriatric Medicine Gynecology Headache Infectious Disease Laboratory General Level of Consciousness Motor Obstetrics Pediatrics Pharmacology Procedure Psychiatry Radiology Seizure Sensory Sports Medicine Surgery Tremor Page Motor Index ALS Cataplexy Dystonia Cervical Guillain Barre Myopathy Myopathy Duchenne Myopathy Myasthenia Gravis Restless Leg Syndrome Epidemiology Prevalance: 5-7 per 100,000 worldwide

87. Grand Rounds Archives OTOLARYNGOLOGY ASPECTS OF amyotrophic lateral sclerosis Troy Callender, MD April 23, 1992. Braun SF. Respiratory system in amyotrophic lateral sclerosis. http://www.bcm.tmc.edu/oto/grand/42392.html

Grand Rounds Archives The information contained within the Grand Rounds Archive is intended for use by doctors and other health care professionals. These documents were prepared by resident physicians for presentation and discussion at a conference held at The Baylor College of Medicine in Houston, Texas. No guarantees are made with respect to accuracy or timeliness of this material. This material should not be used as a basis for treatment decisions, and is not a substitute for professional consultation and/or peer-reviewed medical literature. OTOLARYNGOLOGY ASPECTS OF AMYOTROPHIC LATERAL SCLEROSIS Troy Callender, MD April 23, 1992 Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder of the motor neurons. Most of the morbidity and eventual mortality is primarily the result of the bulbar and respiratory involvement by the disease. Otolaryngologists are frequently consulted to participate in the care of ALS patients and will occasionally be the first physician consulted if bulbar symptoms predominate. Pathologic evaluation in ALS shows symmetric demyelinization of the pyramidal columns and loss of anterior horn cells in the spinal cord and in the motor nuclei of the bulb.

88. SUPPLEMENTARY THERAPEUTIC MEASURES IN AMYOTROPHIC LATERAL SCLEROSIS SUPPLEMENTARY THERAPEUTIC MEASURES IN amyotrophic lateral sclerosis/MOTOR NEURO DISEASE Author David Atkinson. BACKGROUND More http://www.baar.com/atk_rept.htm

SUPPLEMENTARY THERAPEUTIC MEASURES IN AMYOTROPHIC LATERAL SCLEROSIS/MOTOR NEURO DISEASE Author: David Atkinson BACKGROUND: More than 120 years of symptomatic treatment has produced little more then frustration and despair for patient and physician alike. Most likely there will not be a single drug or therapy which will overcome ALS. REVIEW SUMMARY: This recent and on-going study, involving Supplementary Therapeutic Measures in ALS, has produced relevant strategies which have impacted ALS patients significantly, by (1) producing improved quality of life, (2) stabilization and reversal of symptoms, (3) as well as extended life survival. The Combination of Supplementary Therapeutic Measures include: Deprogramming the negative emotional mind-set that occurs when one receives a terminal diagnosis, and replacing the debilitating negative effect with a positive self-empowering thought process -Meditation - Visualization - Guided imagery - Improved family environment - Biofeedback - Spirituality - Massage - Healthy nutrition - Antioxidants. Additionally, a large segment of the ALS population, involved in this study, has used an Electrical application, the The Baar* Battery.

89. Amino Acids For Amyotrophic Lateral Sclerosis / Motor Neuron Disease (Cochrane R All rights reserved. Amino acids for amyotrophic lateral sclerosis / motor neuron disease (Cochrane Review). Parton M, Mitsumoto H, Leigh PN. ABSTRACT. http://www.cochrane.org/cochrane/revabstr/ab003457.htm

From The Cochrane Library, Issue 2, 2004 Amino acids for amyotrophic lateral sclerosis / motor neuron disease (Cochrane Review) Parton M, Mitsumoto H, Leigh PN ABSTRACT Order full review View and/or submit comments What's new in this issue Search abstracts ... Browse by Review Group A substantive amendment to this systematic review was last made on 18 August 2003. Cochrane reviews are regularly checked and updated if necessary. Background: Amyotrophic lateral sclerosis, also known as motor neuron disease, is a progressive neuromuscular disease that causes disability and eventual death. Various amino acid preparations, the three branched-chain amino acids (L-leucine, L-valine and L-isoleucine) or, alternatively, L-threonine have been used as experimental therapy. Objectives: To examine the efficacy of amino acid therapies in prolonging survival and/or slowing the progression of amyotrophic lateral sclerosis/motor neuron disease. Search strategy: We searched the Cochrane Neuromuscular Disease Group trials register (searched February 2003), MEDLINE (from January 1966 to December 2002) and EMBASE (from January 1980 to December 2002) databases and reports of specialist conferences. Authors of known studies were contacted. Selection criteria: We included randomised or quasi-randomised trials of participants with a clinical diagnosis of amyotrophic lateral sclerosis/motor neuron disease treated with all combinations of amino acids. Our primary outcome measure was survival determined by a pooled hazard ratio of all studies. Our secondary outcome measures were (in order of priority): survival at six and 12 months, muscle strength, any validated rating scale of physical function, quality of life, proportion of patients completing therapy and proportion of patients reporting adverse events attributable to treatment.

90. Amyotrophic Lateral Sclerosis, UPMC | University Of Pittsburgh Medical Center, P A comprehensive resource describing the causes, symptoms, diagnosis, and treatment of amyotrophic lateral sclerosis from the health care experts at the http://als.upmc.com/

Home Amyotrophic Lateral Sclerosis Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig's Disease. It is a progressive nervous system disorder that gradually destroys the nerves responsible for muscle movement. Over time, ALS leads to total paralysis of muscle movement, including respiration. Read more Overview Diagnosis Treatment Options ... Contact UPMC Supplemental content provided by HealthGate Data Corp Terms and Conditions

91. Amyotrophic Lateral Sclerosis --  Encyclopædia Britannica amyotrophic lateral sclerosis (ALS) Encyclopædia Britannica Article. MLA style amyotrophic lateral sclerosis. Encyclopædia Britannica. 2004. http://www.britannica.com/eb/article?eu=7386&tocid=0&query=lou gehrig

92. Amyotrophic Lateral Sclerosis --  Britannica Student Encyclopedia amyotrophic lateral sclerosis Britannica Student Encyclopedia. MLA style amyotrophic lateral sclerosis. Britannica Student Encyclopedia. 2004. http://www.britannica.com/ebi/article?eu=333426&query=amyotrophic lateral sclero

93. Amyotrophic Lateral Sclerosis amyotrophic lateral sclerosis,. Print this article, (ALS), condition amyotrophic lateral sclerosis, Fig. 1. MRI, T2weighted axial images. a, b http://www.amershamhealth.com/medcyclopaedia/medical/Volume VI 1/AMYOTROPHIC LAT

Amershamhealth.com Search for: Type a word or a phrase. All forms of the word are searchable. Browse entry words starting with: A B C D ... Other characters Amyotrophic lateral sclerosis, (ALS), condition characterized by progressive muscle weakness, limb and truncal atrophy, and bulbar signs and symptoms. ALS is characterized predominantly by degeneration of both corticospinal tracts as well as lower motor neurons. The extent of corticospinal tract degeneration varies along the neuraxis. On MR examination ( Fig.1 ), hyperintensity is seen on long TR sequences along the course of corticospinal tracts from the precentral gyrus to the level of the cord. This high signal reflects myelin loss and gliosis. T2-weighted images sometimes show low signal within the motor cortex possibly due to iron deposition and indicating degeneration of the cortex. Imaging can also show focal atrophy along the course of the corticospinal tract. The anterior and lateral portions of the spinal cord may be atrophic due to motorneuron loss. LS The Encyclopaedia of Medical Imaging Volume VI:1 Amyotrophic lateral sclerosis, Fig. 1

94. Amyotrophic Lateral Sclerosis (ALS) - For Patients And Families - The Center For For Patients and Families amyotrophic lateral sclerosis (ALS) What is ALS? amyotrophic lateral sclerosis (ALS) is also called Lou Gehrig s disease. http://www.chg.duke.edu/patients/als.html

For Patients and Families Amyotrophic lateral sclerosis (ALS) What is ALS? Genetics and ALS Center for Human Genetics ALS Research ALS Support Organizations What is ALS? Amyotrophic lateral sclerosis (ALS) is also called Lou Gehrig's disease. It is a fatal disorder characterized by progressive degeneration of the motor cells in the spinal cord and brain (central nervous system), which inhibits nerve impulses from being sent to the muscles. Eventually, a person who has ALS experiences muscle weakness and wasting, particularly of the muscles used to move the arms and legs and muscles involved in speech, swallowing, and breathing. The cause is unknown and there currently is no cure for ALS. Genetics and ALS The sporadic form of ALS is the most common form in the United States. People with the sporadic form of ALS do not have any relatives with ALS. There is also an i nherited form of ALS (where multiple members of a family may have ALS) which occurs less frequently. There appear to be both autosomal dominant and autosomal recessive forms of familial ALS. However, it appears that ALS may be caused by

95. Boards - ALS - Amyotrophic Lateral Sclerosis Reload this Page ALS amyotrophic lateral sclerosis. User Name, Remember Me? Password, Threads in Board ALS - amyotrophic lateral sclerosis, Board Tools. http://www.healthboards.com/boards/forumdisplay.php?f=11

96. Amyotrophic Lateral Sclerosis - Eurorad - Clinical Case 1121 - Senior teaching files,radiology,amyotrophic lateral sclerosis,A 49year-old man presented with progressive weakness of the upper and lower extremities associated with http://www.eurorad.org/case.cfm?uid=1121

97. Amyotrophic Lateral Sclerosis - MR Imaging - Eurorad - Clinical Case 1234 - Resi teaching files,radiology,amyotrophic lateral sclerosis MR imaging,A 38-year-old man with progressive weakness of both upper limbs showed bilateral http://www.eurorad.org/case.cfm?uid=1234

98. Disease - Amyotrophic Lateral Sclerosis Please Rate this Page. amyotrophic lateral sclerosis. Disease Name, amyotrophic lateral sclerosis. SearchTerm, Motor neuron disease, Familial http://disability.ucdavis.edu/resources/diseases/list/disease.asp?id=4

99. OHSU Health - Amyotrophic Lateral Sclerosis (ALS) Detailed information on amyotrophic lateral sclerosis, including statistics, types, symptoms, diagnosis, and treatment. amyotrophic lateral sclerosis (ALS). http://www.ohsuhealth.com/htaz/neuro/disorder/amyotrophic_lateral_sclerosis_als.

Nervous System Disorders Home Page Neurological Disorders Acute Spinal Cord Injury Alzheimer's Disease Amyotrophic Lateral Sclerosis (ALS) Bell's Palsy Brain Tumors Epilepsy and Seizures Head Injury ... Email Amyotrophic Lateral Sclerosis (ALS) What is amyotrophic lateral sclerosis (ALS)? Amyotrophic lateral sclerosis (ALS) is a terminal neurological disorder characterized by progressive degeneration of nerve cells in the spinal cord and brain. Often referred to as "Lou Gehrig's disease" (a famous baseball player who died from the disease), it is one of the most devastating of the disorders that affects the function of nerves and muscles. ALS does not affect mental functioning or the senses (such as seeing or hearing), and it is not contagious. Currently, there is no cure for amyotrophic lateral sclerosis. Statistics of ALS: Consider the following statistics regarding ALS: Most people who develop ALS are between the ages of 40 and 70, although the disease can occur at a younger age. ALS occurs throughout the world with no racial, ethnic, or socioeconomic boundaries. ALS affects as many as 30,000 Americans, with 5,600 new cases diagnosed in the US each year.

100. JAMA & Archives -- Topic Collections : Amyotrophic Lateral Sclerosis Institution Tularik Inc Library Sign In as Individual. amyotrophic lateral sclerosis. Contributing journals to this collection JAMA Archives Journals. http://pubs.ama-assn.org/cgi/collection/amyotrophic_lateral_sclerosis

Select Journal or Resource JAMA Archives of Dermatology Facial Plastic Surgery Family Medicine (1992-2000) General Psychiatry Internal Medicine Neurology Ophthalmology Surgery Student JAMA For The Media Classified Ads Meetings Peer Review Congress Amyotrophic Lateral Sclerosis Contributing journals to this collection: JAMA Archives Journals Citations 1-10 of 29 total displayed. Most recent content Editorials A Frontotemporal Family Bridge Andrew Kertesz Arch Neurol 2004; 61: 318. [Extract] [Full text] Observations Tau Mutations With Tau and -Synuclein Inclusions Kirk C. Wilhelmsen, Mark S. Forman, Howard J. Rosen, Loren I. Alving, Jill Goldman, Jennie Feiger, James V. Lee, Samantha K. Segall, Joel H. Kramer, Catherine Lomen-Hoerth, Katherine P. Rankin, Julene Johnson, Heidi S. Feiler, Michael W. Weiner, Virginia M.-Y. Lee, John Q. Trojanowski, and Bruce L. Miller Arch Neurol 2004; 61: 398-406. [Abstract] [Full text] Past content Food Chain of Evidence Points to Brain Toxin Tracy Hampton JAMA 2003; 290: 2788-2789.

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 5     81-100 of 113    Back | 1  | 2  | 3  | 4  | 5  | 6  | Next 20